Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary EndpointsGlobeNewsWire • 04/29/21
Phantom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 ReadoutsSeeking Alpha • 04/07/21
Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/21
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business ProgressGlobeNewsWire • 03/30/21
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) TrialGlobeNewsWire • 01/19/21
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences TeamBusiness Wire • 01/07/21
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common StockGlobeNewsWire • 12/15/20
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)GlobeNewsWire • 12/14/20
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis TrialGlobeNewsWire • 11/30/20
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare ConferencesGlobeNewsWire • 11/27/20
Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare ConferenceGlobeNewsWire • 11/13/20
Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare ConferenceGlobeNewsWire • 09/09/20
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial OfficerGlobeNewsWire • 07/13/20
Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020Seeking Alpha • 02/19/20